• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Fluoroquinolones compared in corneal healing


Fort Lauderdale, FL—Results from a preclinical study indicate that fluoroquinolones available for ophthalmic use may differ in their effects on corneal healing, said Luis E. Fern?ndez de Castro, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.

The study was conducted at the Magill Research Center for Vision Correction, Storm Eye Institute, Medical University of South Carolina, Charleston, where Dr. Fernández de Castro is a research instructor.

A total of 36 New Zealand white rabbits were divided into six treatment groups. All animals underwent an 8-mm anterior keratectomy in both eyes and then received four times daily treatment for 5 days with one of five different ophthalmic fluoroquinolones or balanced salt solution (BSS).

Mean epithelial healing rates were also slower in the moxifloxacin 0.5% (23.9 µm/h) and levofloxacin 0.5% (21.8 µm/h) groups compared with gatifloxacin (26 µm/h), ofloxacin (34.3 µm/h), and BSS (26 µm/h). The slowest rate of epithelial migration was in ciprofloxacin-treated eyes (19.7 µm/h).

"Surgical prophylaxis is an essential component of cataract and refractive surgery in order to avoid potentially devastating complications," Dr. Fernández de Castro said. "However, it is important that any prophylactic treatment not interfere with natural corneal wound healing.

While all topical antibiotics used for surgical prophylaxis have been associated with some degree of toxicity to the corneal epithelium, the researchers were interested in characterizing the effects of the older fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin) relative to the fourth-generation agents moxifloxacin and gatifloxacin, which are being advocated for prophylaxis because of their greater antimicrobial potency and reduced association with resistance.

To minimize potential confounding, all animals included in the study had similar characteristics (age, gender, and weight) and all of the outcome assessments were made in a masked fashion. Wound healing rates were determined by analyzing slit-lamp microphotographs of fluorescein-stained eyes taken twice daily beginning at 24 hours after anterior keratectomy. Those studies showed that all wounds healed in a symmetric fashion and with a decrease in wound radius that was constant over time.

Three animals in each treatment group were killed after 48 hours for immunohistochemical evaluation of collagen expression in the cornea, and the remaining animals were killed after 96 hours.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.